(0.65%) 5 160.99 points
(0.26%) 38 778 points
(0.71%) 16 271 points
(0.20%) $78.27
(4.06%) $2.23
(1.06%) $2 333.10
(3.34%) $27.58
(-0.09%) $964.45
(-0.08%) $0.928
(-0.45%) $10.83
(-0.16%) $0.796
(-0.12%) $91.34
Live Chart Being Loaded With Signals
Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress...
Stats | |
---|---|
今日成交量 | 1.00 |
平均成交量 | 0.00 |
市值 | 4.00 |
EPS | $-1.740 ( 2021-05-14 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 0 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2014-02-24 | Paulson Capital (delaware) Corp. | Buy | 500 000 | Common Stock |
2014-02-24 | Paulson Cardax Investments 1 Llc | Buy | 500 000 | Common Stock |
2014-02-07 | Paulson Capital (delaware) Corp. | Buy | 1 068 477 | Warrants (right to buy) |
2014-02-07 | Paulson Cardax Investments 1 Llc | Buy | 1 068 477 | Warrants (right to buy) |
2014-02-07 | Paulson Capital (delaware) Corp. | Buy | 0 | Common Stock |
INSIDER POWER |
---|
0.00 |
Last 4 transactions |
Buy: 3 136 954 | Sell: 0 |
音量 相关性
Cardax, Inc. 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Cardax, Inc. 相关性 - 货币/商品
Cardax, Inc. 财务报表
Annual | 2022 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $0 |
FY | 2022 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $0 |
FY | 2020 |
营收: | $538 946 |
毛利润: | $342 816 (63.61 %) |
EPS: | $-6.79 |
FY | 2019 |
营收: | $710 949 |
毛利润: | $365 556 (51.42 %) |
EPS: | $-7.49 |
Financial Reports:
No articles found.
Cardax, Inc.
Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia; and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax, Inc. is based in Honolulu, Hawaii.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。